Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer.

Next Previous
Trial Profile

A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer.

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anastrozole (Primary) ; Exemestane (Primary) ; Antineoplastics; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Letrozole; Paclitaxel; Tamoxifen
  • Indications Early breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms RxPONDER

Most Recent Events

  • 04 Jun 2024 Results (n=1015) assessing the prognostic value of serum anti-Mullerian hormone (AMH) levels as an indicator of adjuvant chemotherapy benefits in HR+, HER2-negative invasive breast cancer, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 24 May 2024 According to EXACT Sciences Corporation media release, company will present abstracts highlighting the breadth and depth of the companys screening and diagnostic portfolio at the American Society of Clinical Oncology Annual Meeting, taking place May 31 to June 4, 2024, in Chicago, Ill.
  • 07 May 2013 National Cancer Institute of Canada reports actual initiation date as 5 Oct 2011.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top